Roche Pharmaceutical Development and Sales Overview

Balovaptan (RG7314) Small molecule antagonist of the V1A vasopressin receptor Indication Phase/study Post-traumatic stress disorder (PTSD) Phase II # of patients N=252 ARM A: Balovaptan (IV) once a day for 12 weeks ARM B: Placebo matched control Design Primary endpoint Change from baseline in the Clinician-Administered PTSD Total Symptom Severity Score Status CT Identifier FPI Q3 2022 NCT05401565 127 Roche Neuroscience

View entire presentation